{"id":"756de1e6-c61b-5907-8dbf-784e01074f0e","stable_key":"c94a9824-35fb-523c-b421-dc7341218dcb:indicaxanthin-endothelial-icam1","predicate":"reduces_induced_expression","statement":"Indicaxanthin pretreatment reduced oxidized-LDL-induced ICAM1 mRNA and protein increases in HUVECs.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"6e5ee24f-a398-5470-af00-efd3320e17aa","mechanism_event_label":"Indicaxanthin pretreatment reduced oxidized-LDL-induced ICAM1 mRNA and protein increases in HUVECs.","subject":{"id":"f2a6e469-05f0-5596-9054-da926389f584","slug":"indicaxanthin","display_name":"Indicaxanthin","entity_type_key":"small_molecule"},"object":{"id":"73fdab07-975f-5669-8cf4-298634556a04","slug":"human-icam1","display_name":"Human intercellular adhesion molecule 1 / ICAM1","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"6e5ee24f-a398-5470-af00-efd3320e17aa","stable_key":"c94a9824-35fb-523c-b421-dc7341218dcb:indicaxanthin-endothelial-icam1-event","event_type":"observed_relationship","label":"Indicaxanthin pretreatment reduced oxidized-LDL-induced ICAM1 mRNA and protein increases in HUVECs.","description":"Indicaxanthin pretreatment reduced oxidized-LDL-induced ICAM1 mRNA and protein increases in HUVECs.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"f2a6e469-05f0-5596-9054-da926389f584","slug":"indicaxanthin","display_name":"Indicaxanthin","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"73fdab07-975f-5669-8cf4-298634556a04","slug":"human-icam1","display_name":"Human intercellular adhesion molecule 1 / ICAM1","entity_type_key":"protein"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"f2f4e414-62e7-51fa-bbf3-81b81a53701e","slug":"human-oxidized-ldl-preparation","display_name":"Oxidized human LDL preparation","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"dose","value_text":"Indicaxanthin 5-20 micromolar; human oxidized LDL 100 micrograms/mL","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"1 h pretreatment followed by 16 h oxidized-LDL exposure","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary open full text, relevant results/methods and PubMed metadata.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_scope","value_text":"literature_reviewed; model-specific source-derived curation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human umbilical vein endothelial cells / HUVECs","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Expression rescue does not demonstrate plaque regression or ABCA1 cholesterol-efflux flux. Primary-source metadata check found no correction/retraction link; broader integrity not assessed.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Dedicated indicaxanthin chapter; original betalain family identity and shared claims preserved.","comparator":null,"unit":null,"notes":"","entity":{"slug":"indicaxanthin","display_name":"Indicaxanthin","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human umbilical vein endothelial cells / HUVECs","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Indicaxanthin pretreatment reduced oxidized-LDL-induced ICAM1 mRNA and protein increases in HUVECs.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Indicaxanthin from Opuntia ficus indica (L. Mill) Inhibits Oxidized LDL-Mediated Human Endothelial Cell Dysfunction through Inhibition of NF-κB Activation. (2019). https://pubmed.ncbi.nlm.nih.gov/30911345/ DOI: 10.1155/2019/3457846","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"In vitro pretreatment and challenge","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Endothelial culture","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"7bfe5516-2614-51e2-ab02-a1f12d069ee0","evidence_kind":"source_excerpt","locator":"Lines 360-369","start_line":360,"end_line":369,"excerpt":"## indicaxanthin-endothelial-icam1\nIndicaxanthin pretreatment reduced oxidized-LDL-induced ICAM1 mRNA and protein increases in HUVECs.\nModel/species: Human umbilical vein endothelial cells / HUVECs\nTissue: Endothelial culture\nExposure: Indicaxanthin 5-20 micromolar; human oxidized LDL 100 micrograms/mL\nRoute: In vitro pretreatment and challenge\nDuration: 1 h pretreatment followed by 16 h oxidized-LDL exposure\nLimits: Expression rescue does not demonstrate plaque regression or ABCA1 cholesterol-efflux flux. Primary-source metadata check found no correction/retraction link; broader integrity not assessed.\nPrimary reference: Indicaxanthin from Opuntia ficus indica (L. Mill) Inhibits Oxidized LDL-Mediated Human Endothelial Cell Dysfunction through Inhibition of NF-κB Activation. (2019). https://pubmed.ncbi.nlm.nih.gov/30911345/ DOI: 10.1155/2019/3457846\nAccess: Primary open full text, relevant results/methods and PubMed metadata.","model_system":"Human umbilical vein endothelial cells / HUVECs","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact archived curation span; original paraphrase with primary citation.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"18b7303c-98b7-54cb-ae8e-a8c6257657b1","stable_key":"import-c94a9824-35fb-523c-b421-dc7341218dcb","title":"Indicaxanthin: mechanisms, molecular forms and cross-actor connections (2026-09-20)","document_type":"imported_text","citation_label":"Original AI-assisted curation of thirteen additional primary studies, with twenty-six existing claims from eight studies linked unchanged. Study-specific citations and limitations retained. Not publisher full text.","file_path":"","sha256":"fd5e7b3a108073af5a8cad0e226a483ae2cda3b0e1daed387553ee441acecd5f","revision_id":"f3357c22-1be7-5502-b4f5-415d19c3cf5a","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}